BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for perinatal

Signature Biologics Announces Entry Into the Perinatal Allograft Tissue Market With Commercially Available Flowable Umbilical Cord and Amniotic Allograft Tissue Products

By

Signature Matrix and Signature Cord are the culmination of decades of research and clinical use of perinatal tissue by applied stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and his experienced research and development team.

Signature Cord is a flowable umbilical cord tissue allograft that originates from the same tissue used to manufacture the purified, expanded mesenchymal stem cell product used by Stem Cell Institute in Panama to treat a variety of chronic conditions. This product is a natural source of growth factors and hyaluronic acid, and is naturally immune evasive. Most importantly, our proprietary Signature Process of manufacturing does not alter the innate regenerative properties of the umbilical cord tissue and maintains the source material integrity required for tissue repair. [Read more…]

Cord Blood Banking Market Consolidation

By

After a rapid growth period through the mid-2000s, the global cord blood banking market reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating.

In this article:

  1. Cord Blood Industry Consolidation in the U.S.
  2. Cord Blood Industry Consolidation in Europe
  3. Cord Blood Industry Consolidation in Asia
  4. Cord Blood Industry Consolidation in Latin America
  5. Cord Blood Industry Consolidation in India
  6. Trend of Umbilical Cord Blood Industry Consolidation

[Read more…]

Evolution of the Cord Blood Banking Market – Transplant Medicine to RM to Longevity

By

Cord blood banking initially emerged as a commercial service in the late 1980’s and early 1990’s, because of potential applications related to Transplant Medicine. While an effective therapeutic approach, this unfortunately produced low utilization rates for stored cord blood units.

As a result, Regenerative Medicine (RM) applications of cord blood emerged over time, expanding approved used for cord blood to approximately 80 total. Exciting regenerative medicine applications for umbilical cord blood include its potential to treat neurological conditions, such as cerebral palsy (CP) and autism. These applications are being researched by one of the luminaries in the field, Dr. Joanne Kurtzberg of the Duke Center for Autism and Brain Development and the Carolinas Cord Blood Bank.

As the cord blood market has expanded to include a wide range of perinatal tissues, including umbilical cord tissue, placental blood and tissue, and amniotic fluid and tissue, the new frontier has become Longevity applications. Perinatal is a term describing the period right before and after birth. [Read more…]

Best Cord Blood Banking Conferences

By

Cord blood conferences have been expanding in number and frequency over the past decade. Cord blood banking is the long-term storage and preservation of umbilical cord blood collected during the birth of a newborn. It is collected, because it is rich in hematopoietic stem cells (HSCs), a stem cell type that is widely used in transplant medicine and can be used to treat over 80 different conditions. The matrix of the umbilical cord, called Wharton’s Jelly, is also a rich source of mesenchymal stem cells (MSCs), a cell type that is now being explored in more than 800 clinical trials worldwide.

Each year, cord blood industry experts gather at these events to discuss trends, research progress, and clinical and technological advances.

Below, we highlight leading cord blood industry events, many of which BioInformant attends, sponsors, or helps to organize. [Read more…]

Amniotic Stem Cells: An Extension of the Cord Blood Banking Model

By

Amniotic stem cells, which can be sourced from the amniotic fluid or the placenta after a live, healthy birth, possess a unique blend of multipotency and lack of tumorigenicity. In an extension of the cord blood banking model, these cells may improve outcomes where long-term cell survival and functionality is important. Recently, I had the honor of interview Dr. Todd McAllister, Executive Director at the Amnion Foundation, a non-profit organization with the mission to build a genetically diverse public cell bank that can provide an immunological match to the majority of the population.

Amnion Foundation In this interview, we discuss the Amnion Foundation’s vision, research and clinical approach, scale-out strategy, and interest in joint partnerships that will support greater utilization of amniotic stem cells. It is captivating to get an insider look at the Amnion Foundation, a non-profit that is introducing a new extension to the traditional cord blood and tissue banking market.

As the cord blood banking market matures and consolidates and diversifies into new types of perinatal stem cell storage, the Amnion Foundation will be uniquely positioned to advise cord blood banks on how to integrate amniotic stem cell banking into their service portfolio.

[Read more…]

BioInformant's World-Class Clients